Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — Investor Presentation (January 2024)

39 slides from Day One Biopharmaceuticals's investor presentation, Jan 8, 2024

  1. Slide 1: Day One Biopharmaceuticals: Targeted Therapies for People of All Ages

    Slide 1: Day One Biopharmaceuticals: Targeted Therapies for People of All Ages

    Exhibit 99.2 Day One Biopharmaceuticals Targeted Therapies for People of All Ages January 2024 1

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some

  3. Slide 3: Cancer Therapies for People of All Ages

    Slide 3: Cancer Therapies for People of All Ages

    Cancer Therapies for People of All Ages Our Approach • Develop medicines for genomically-defined cancers • Establish first-in-class position through rapid registration pathways • Expand to adolescent and adult populations in parallel and pursue those opportunities with the same commitment we do for

  4. Slide 4: Our Pipeline

    Slide 4: Our Pipeline

    Our Pipeline Recent & Anticipated Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Milestones Tovorafenib (DAY101) FDA acceptance of NDA: October 2023 Type II RAF Inhibitor PDUFA target action date: 1 Relapsed pLGG FIREFLY-1 (pivotal) April 30, 2024 • FDA Breakthrough Therapy Data pu

  5. Slide 5: Tovorafenib (DAY101) Type II RAF Inhibitor

    Slide 5: Tovorafenib (DAY101) Type II RAF Inhibitor

    Tovorafenib (DAY101) Type II RAF Inhibitor 5

  6. Slide 6: Kids like Sawyer spend most of their childhood as patients rather than children

    Slide 6: Kids like Sawyer spend most of their childhood as patients rather than children

    Kids like Sawyer spend most of their childhood as patients rather than children 3 (1-9) 51% Median (range) number of lines Percentage of patients who 1 of prior systemic therapy had greater than or equal to 3 1 lines of prior systemic therapy 1 6 Sawyer, lives with pLGG. Figures come from FIREFLY-1

  7. Slide 7: Pediatric Low-Grade Glioma: The Most Common Type of Brain Tumor in Children

    Slide 7: Pediatric Low-Grade Glioma: The Most Common Type of Brain Tumor in Children

    Pediatric Low-Grade Glioma (pLGG): The Most Common Type Of Brain Tumor In Children pLGGs are chronic and relentless, with patients suffering profound tumor and treatment- 6 associated morbidity that can impact their life trajectory over the long term 7 A Serious and Life-Threatening Disease Disease

  8. Slide 8: Conventional Treatments Can Be Disruptive To Childhood

    Slide 8: Conventional Treatments Can Be Disruptive To Childhood

    Conventional Treatments Can Be Disruptive To Childhood and Can Have Significant Long-Term Consequences Surgery Chemotherapy Radiation • Significant recovery times • Requirement for indwelling • Risk of secondary malignancy catheter and weekly infusions • Risks of complications • Risk of malignant tr

  9. Slide 9: Tovorafenib Inhibits Both BRAF Fusions And BRAF V600 Mutations

    Slide 9: Tovorafenib Inhibits Both BRAF Fusions And BRAF V600 Mutations

    Tovorafenib (DAY101) Inhibits Both BRAF Fusions And BRAF V600 Mutations MAPK pathway RAS-independent activation of the MAPK pathway Tovorafenib (DAY101) is an investigational, oral, selective, CNS- penetrant, type II RAF inhibitor that was RAS designed to inhibit both monomeric and dimeric RAF kinas

  10. Slide 10: Pivotal Phase Trial Of Tovorafenib In Relapsed Or Progressive pLGG (FIREFLY-1)

    Slide 10: Pivotal Phase Trial Of Tovorafenib In Relapsed Or Progressive pLGG (FIREFLY-1)

    Pivotal Phase 2 Trial Of Monotherapy Tovorafenib (DAY101) In Relapsed Or Progressive pLGG (FIREFLY-1) – Fully Enrolled & Data Accepted by FDA Trial Design Endpoints (Pivotal Arm 1) 1 • Three arm, open-label, global registrational phase 2 trial • Primary endpoint: ORR based on RANO-HGG , assessed by

  11. Slide 11: Data from Pivotal Phase FIREFLY-1 Trial

    Slide 11: Data from Pivotal Phase FIREFLY-1 Trial

    Data from Pivotal Phase 2 FIREFLY-1 Trial June 5, 2023 data cutoff 11

  12. Slide 12: FIREFLY-1 Baseline Patient Characteristics

    Slide 12: FIREFLY-1 Baseline Patient Characteristics

    FIREFLY-1 Baseline Patient Characteristics Characteristic Arm 1 (n=77) Location (n=77) Deep midline structures Optic pathway Median age, years (range) 8 (2-21) 12% 51% Sex, n (%) Other Male 40 (52) † 16% Female 37 (48) Cerebral hemisphere 8% Race, n (%) Cerebellum Brain stem White 41 (53) 6% 8% Asia

  13. Slide 13: Tumor Response To Tovorafenib Using RAPNO-LGG, RANO-LGG and RANO-HGG

    Slide 13: Tumor Response To Tovorafenib Using RAPNO-LGG, RANO-LGG and RANO-HGG

    Tumor Response To Tovorafenib (DAY101) Using RAPNO-LGG, RANO-LGG and RANO-HGG RAPNO-LGG RAPNO-LGG RANO-LGG RANO-HGG Response (IRC) n=76 N=76 N=69 ORR,* n (%) 39 (51) 40 (53) 46 (67) 95% CI 40-63 41-64 54-78 CBR,* n (%) 62 (82) 63 (83) 64 (93) SD of any length of time 43 (57) 46 (61) 54 (78) SD ≥12 m

  14. Slide 14: Duration Of Tovorafenib Therapy For Patients With RAPNO-LGG Evaluable Lesions

    Slide 14: Duration Of Tovorafenib Therapy For Patients With RAPNO-LGG Evaluable Lesions

    Duration Of Tovorafenib (DAY101) Therapy For All Patients With RAPNO-LGG Evaluable Lesions 5.3 Median time to response Months Median duration of 13.8 treatment Months Overall treatment duration (months) 14 June 5, 2023 data cutoff. Patients

  15. Slide 15: Tumor Kinetics In Patients With Best Response Of Progressive Disease

    Slide 15: Tumor Kinetics In Patients With Best Response Of Progressive Disease

    Tumor Kinetics In Patients With Best Response Of Progressive Disease According To RAPNO-LGG The majority of patients who had radiographic progression by RAPNO-LGG at their initial disease assessment had subsequent prolonged reductions in the size of their tumor with continued treatment. Months 15 Ju

  16. Slide 16: Tumor Response According To RAPNO-LGG In Subgroups

    Slide 16: Tumor Response According To RAPNO-LGG In Subgroups

    Tumor Response To Tovorafenib (DAY101) According To RAPNO-LGG In Subgroups Defined By Baseline Characteristics Male (n=40) Female (n=36) 6 months-<2 years of age (n=0) 2-<6 years of age (n=14) 6-<12 years of age (n=40) Analysis of response data across various subgroups shows no 12-<16 years of age (

  17. Slide 17: Tumor Response Across Three Assessment Criteria Consistent Across Subgroups

    Slide 17: Tumor Response Across Three Assessment Criteria Consistent Across Subgroups

    Tumor Response To Tovorafenib (DAY101) Across Three Assessment Criteria Were Consistent Across BRAF Fusion And Mutation Patients, and Patients With Prior MAPK Treatment 2 3,4 1 RAPNO-LGG RANO-LGG RANO-HGG Response (IRC) n n n ORR,* n (%) 76 39 (51) 76 40 (53) 69 46 (67) BRAF fusion 64 33 (52) 64 33

  18. Slide 18: Tovorafenib Safety Data (n=137)

    Slide 18: Tovorafenib Safety Data (n=137)

    Tovorafenib (DAY101) Safety Data (n=137) TEAEs TRAEs Preferred Term, n (%) Any Grade Grade ≥3 Any Grade Grade ≥3 Any AE 137 (100) 86 (63) 134 (98) 58 (42) Hair color changes 104 (76) 0 104 (76) 0 • The most common reasons Anemia 81 (59) 15 (11) 67 (49) 14 (10) Elevated CPK 80 (58) 16 (12) 77 (56) 16

  19. Slide 19: Estimated BRAF-Altered pLGG Patient Population In The U.S.

    Slide 19: Estimated BRAF-Altered pLGG Patient Population In The U.S.

    Estimated BRAF-Altered pLGG Patient Population In The U.S. ~26,000 Prevalence of Systemically- ~2,000-3,000 Treated Patients 1-5 ~1,100 Under 25 Recurrent/Progressive Total Addressable Incidence of Patient Population Treatment- 6 per Year Eligible Frontline 4,5 Patients The estimated addressable poo

  20. Slide 20: Preparing for a Successful Launch

    Slide 20: Preparing for a Successful Launch

    * Preparing for a Successful Launch Key Factors Priorities • Communicate strong clinical profile for Drive FIREFLY-1 Trial and Physician tovorafenib without significant disruption to Awareness childhood • Enable patient access through establishing Build momentum with pediatric broad coverage and pat

  21. Slide 21: Key Takeaways From FIREFLY-1 Data And Next Steps

    Slide 21: Key Takeaways From FIREFLY-1 Data And Next Steps

    Key Takeaways From FIREFLY-1 Data And Next Steps • Response rate is clinically meaningful from FIREFLY-1 for pediatric patients with recurrent or progressive LGG harboring BRAF fusions or BRAF V600E mutations (“BRAF-altered”) • 67% ORR by RANO-HGG • 51% ORR by RAPNO-LGG • 53% ORR by RANO-LGG • Deepe

  22. Slide 22: FIREFLY-2 / LOGGIC Pivotal Phase Trial in Frontline pLGG

    Slide 22: FIREFLY-2 / LOGGIC Pivotal Phase Trial in Frontline pLGG

    FIREFLY-2 / LOGGIC Pivotal Phase 3 Trial of Tovorafenib (DAY101) in Frontline pLGG 22

  23. Slide 23: FIREFLY-2/LOGGIC Pivotal Phase Trial In Frontline pLGG

    Slide 23: FIREFLY-2/LOGGIC Pivotal Phase Trial In Frontline pLGG

    FIREFLY-2/LOGGIC Pivotal Phase 3 Trial Of Tovorafenib (DAY101) In Frontline pLGG Trial Design Endpoints • Randomized, global, registrational Phase 3 trial of monotherapy tovorafenib • Primary endpoint: ORR based on RANO-LGG criteria, assessed by 1 (DAY101) vs SoC chemotherapy blinded independent cen

  24. Slide 24: FIRELIGHT-1 Phase 1b/2 Trials of Tovorafenib with Pimasertib

    Slide 24: FIRELIGHT-1 Phase 1b/2 Trials of Tovorafenib with Pimasertib

    FIRELIGHT-1 Phase 1b/2 Trials Evaluating Tovorafenib (DAY101) as a Combination with Pimasertib 24

  25. Slide 25: Pimasertib: Investigational Allosteric MEK1/2 Inhibitor

    Slide 25: Pimasertib: Investigational Allosteric MEK1/2 Inhibitor

    Pimasertib: Investigational Allosteric MEK1/2 Inhibitor With Demonstrated Activity In MAPK-Driven Solid Tumors • Pimasertib is an investigational orally-bioavailable, selective, non- competitive MEK1/2 inhibitor in-licensed from Merck KGaA in February 2021 • Extensive non-clinical and clinical devel

  26. Slide 26: Vertical MAPK Pathway Inhibition With Tovorafenib And Pimasertib

    Slide 26: Vertical MAPK Pathway Inhibition With Tovorafenib And Pimasertib

    Vertical MAPK Pathway Inhibition With Tovorafenib (DAY101) And Pimasertib May Unlock Potential Synergy For Adult Solid Tumors BRAF KRAS or NRAS non-V600 mutant mutant MEK RAF/ PI3K/m PI3K/m MEK/ERK TOR TOR ERK Proliferation, survival Proliferation, survival Type II RAFi + MEKI Type II RAFi + MEKI A

  27. Slide 27: Tovorafenib / Pimasertib Combination In Solid Tumors (FIRELIGHT-1)

    Slide 27: Tovorafenib / Pimasertib Combination In Solid Tumors (FIRELIGHT-1)

    Tovorafenib (DAY101) / Pimasertib Combination In Solid Tumors (FIRELIGHT-1) 1 Trial Design Endpoints 2 • Combination dose escalation, global phase 1b/2 trial • Phase 1b: PK, PD and Safety, MTD/RP2D • Phase 1b, BOIN (adaptive), n = 10/cohort (approximately) • Phase 2: Efficacy (ORR, DOR) • Phase 2, S

  28. Slide 28: Summary

    Slide 28: Summary

    Summary 28

  29. Slide 29: Financial Summary: DAWN

    Slide 29: Financial Summary: DAWN

    Financial Summary: DAWN Cash, cash equivalents and short-term investments as of ~87.0 million shares of common stock outstanding as September 30, 2023: $405.5 million (no debt) of November 1, 2023 Nine Months Ended Nine Months Ended $ Millions 9/30/23 9/30/22 R&D Expense $93.2 $59.6 G&A Expense $53.

  30. Slide 30: 2023 Key Accomplishments

    Slide 30: 2023 Key Accomplishments

    FIREFLY-1: Relapsed or Progressive pLGG • NDA initiated in May 2023 • Clinical data presented in oral presentation at ASCO in June 2023 • FDA acceptance of NDA and priority review granted in October 2023 • Data published in Nature Medicine and oral presentation at SNO in November 2023 2023 Key • PDU

  31. Slide 31: Priorities as we Expand into a Commercial-Stage Company

    Slide 31: Priorities as we Expand into a Commercial-Stage Company

    Priorities as we Expand into a Commercial-Stage Company Launch Tovorafenib Advance Portfolio Expand Pipeline • Secure the first FDA-approved • FIREFLY-2: Study tovorafenib as a • Grow Day One into a leading, targeted therapy for pLGG with frontline therapy for treatment- biopharmaceutical company th

  32. Slide 32: Appendix

    Slide 32: Appendix

    a oS] oO | o a <x

  33. Slide 33: Duration Of Tovorafenib Therapy For Patients With RANO-HGG Evaluable Lesions

    Slide 33: Duration Of Tovorafenib Therapy For Patients With RANO-HGG Evaluable Lesions

    Duration Of Tovorafenib (DAY101) Therapy For All Patients With RANO-HGG Evaluable Lesions 3.0 Median time to response Months Median duration of 16.6 treatment Months Overall treatment duration (months) 33 June 5, 2023 data cutoff. Patients

  34. Slide 34: Duration Of Tovorafenib Therapy For Patients With RANO-LGG Evaluable Lesions

    Slide 34: Duration Of Tovorafenib Therapy For Patients With RANO-LGG Evaluable Lesions

    Duration Of Tovorafenib (DAY101) Therapy For All Patients With RANO-LGG Evaluable Lesions 5.5 Median time to response Months Median duration of 14.4 treatment Months Overall treatment duration (months) 34 June 5, 2023 data cutoff. Patients

  35. Slide 35: Case Study: Tovorafenib In KIAA1549-BRAF Fusion Optic Pathway Glioma

    Slide 35: Case Study: Tovorafenib In KIAA1549-BRAF Fusion Optic Pathway Glioma

    Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Optic Pathway Glioma A 7-years-old female child with an optic pathway glioma, with very poor vision, entropion, folliculitis, eczema, mouth ulceration and xerosis -36 -30 -24 -18 -12 -6 0 6 Months PR 1L: Vincristine/carboplatin Dia

  36. Slide 36: Case Study: Tovorafenib In KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma

    Slide 36: Case Study: Tovorafenib In KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma

    Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma An 8-years-old female child with a posterior fossa pilocytic astrocytoma, eczema, nausea and constipation -84 -72 -60 -48 -36 -24 -12 0 12 Months PR Suboccipital craniotomies 1L: Carboplatin 2L

  37. Slide 37: Case Study: Tovorafenib In BRAF V600E Mutation Deep Midline Astrocytoma

    Slide 37: Case Study: Tovorafenib In BRAF V600E Mutation Deep Midline Astrocytoma

    Case Study: Activity Of Tovorafenib (DAY101) In BRAF V600E Mutation Deep Midline Astrocytoma A 9-year-old female child with deep midline BRAF V600E-mutant astrocytoma with precocious puberty -60 -48 -36 -24 -12 0 12 Months PR Subtotal 1L: Carboplatin/vincristine 2L: Dabrafenib 3L: Tovorafenib Best r

  38. Slide 38: Case Study: Tovorafenib In KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma

    Slide 38: Case Study: Tovorafenib In KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma

    Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma 8-year-old boy with relapsed pilomyxoid astrocytoma of the optic pathway, with visual loss in right eye, visual field loss in left eye, fatigue, intermittent nausea/vomiting, intermittent heada

  39. Slide 39: FIREFLY-2/LOGGIC: Pivotal Phase Study In Newly Diagnosed pLGG

    Slide 39: FIREFLY-2/LOGGIC: Pivotal Phase Study In Newly Diagnosed pLGG

    FIREFLY-2/LOGGIC: Pivotal Phase 3 Study Of Tovorafenib (DAY101) In Newly Diagnosed pLGG • Collaboration between Day One Approximately 100 potential sites (~65 from the LOGGIC consortium) and the LOGGIC consortium, internationally recognized experts in pLGG research • Coupled with the LOGGIC-CORE mol

Source: SEC EDGAR · 8-K filed Jan 8, 2024

More decks from Day One Biopharmaceuticals Inc